Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases.
Ioana Agache, Isabella Annesi-Maesano, Andreas Bonertz, Francesco Branca, Andrew Cant, Zlatko Fras, Frank Ingenrieth, Leyla Namazova-Baranova, Mikaela Odemyr, Antonio Spanevello, Stefan Vieths, Arzu Yorgancioglu, Montserat Alvaro-Lozano, Domingo Barber Hernandez, Tomás Chivato, Stefano Del Giacco, Zuzana Diamant, Ibon Eguiluz-Gracia, Roy Gert van Wijk, Philippe Gevaert, Anke Graessel, Peter Hellings, Karin Hoffmann-Sommergruber, Marek Jutel, Susanne Lau, Antti Lauerma, Jose Maria Olaguibel, Liam O'Mahony, Cevdet Ozdemir, Oscar Palomares, Oliver Pfaar, Joaquin Sastre, Glennis Scadding, Carsten Schmidt-Weber, Peter Schmid-Grendelmeier, Mohamed Shamji, Isabel Skypala, Monica Spinola, Otto Spranger, Maria Torres, Andrea Vereda, Sergio Bonini
Journal: Allergy
2020;74(11):2064-2076
PMID: 31070805
Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Address:
Transylvania University, Brasov, Romania.; Department of Epidemiology of Allergic and Respiratory Diseases, Medical School Saint Antoine, IPLESP, INSERM and Sorbonne Université, Paris, France.; Federal Agency for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany.; Department of Nutrition for Health and Development, Geneva, Switzerland.; WHO/HQ, Geneva, Switzerland.; University of Newcastle Upon Tyne, Newcastle upon Tyne, UK.; European Society for Immunodeficiencies, Geneva, Switzerland.; Division of Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.; UEMS - Union Europeenne des Medecins Specialistes/European Union of Medical Specialists, Brussels, Belgium.; SCOPE Europe, Bruxelles, Belgium.; Department of Pediatrics, Russian National Research Medical University of MoH RF, Moscow, Russia.; Department of Pediatrics, Central Clinical Hospital of MoSHE (Ministry of Science and High Education), Moscow, Russian Federation.; European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium.; Dipartimento di Medicina e Chirurgia, Malattie dell'Apparato Respiratorio, Università degli Studi dell'Insubria, Varese - Como, Italy.; Dipartimento di Medicina e Riabilitazione Cardio Respiratoria, U.O. di Pneumologia Riabilitativa, Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Tradate, Italy.; Department of Pulmonology, Celal Bayar University School of Medicine, Manisa, Turkey.; Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain.; Department of Basic Medical Sciences, School of Medicine, Universidad CEU San Pablo, Madrid, Spain.; RETIC ARADYAL RD16/0006/0015, Instituto de Salud Carlos III, Madrid, Spain.; School of Medicine, University CEU San Pablo, Madrid, Spain.; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.; Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden.; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.; Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain.; ARADyAL Network RD16/0006/0001, Carlos III Health Institute, Madrid, Spain.; Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.; Department of Otorhinolaryngology-Head and Neck Surgery, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.; Allergy Therapeutics, Worthing, UK.; Bencard Allergie GmbH, Munich, Germany.; Department of Otorhinolaryngology-Head and Neck Surgery, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium.; Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium.; Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands.; Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.; Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.; "ALL-MED" Medical Research Institute, Wroclaw, Poland.; Department for Pediatric Pneumology, Immunology and Intensive Care, Charité Universität Medizin, Berlin, Germany.; Dermatology and Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.; Severe Asthma Unit, Complejo Hospitalario de Navarra, Pamplona, Spain.; Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.; Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.; Department of Pediatrics, Division of Pediatric Allergy & Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.; Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.; Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.; Department of Allergy, Fundación Jimenez Diaz, Madrid, Spain.; Department of Medicine, Instituto Carlos III, CIBERES, Universidad Autónoma de Madrid, Madrid, Spain.; RNTNE Hospital, London, UK.; Zentrums Allergie & Umwelt (ZAUM), Technische Universität und Helmholtz Zentrum, München, Germany.; Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.; Christine-Kühne Center for Allergy Research and Education CK-CARE Davos, Davos, Switzerland.; Allergy & Clinical Immunology, Inflammation, Repair and Development, Imperial College, National Heart and Lung Institute, Immunomodulation and Tolerance Group, London, UK.; Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.; Royal Brompton & Harefield NHS Foundation Trust, London, UK.; Imperial College, London, UK.; European Medical Affairs, Sanofi, Milan, Italy.; Global Allergy and Asthma Patient Platform, Vienna, Austria.; Aimmune Therapeutics, London, UK.; Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy.
Link outs
Free resources
Full Text Sources:
Medical:
Subscription / membership required
MeSH Terms:
Asthma,
Big Data,
Bioengineering,
Capital Financing,
Disease Management,
Drug Development,
Environmental Health,
Europe,
Health Policy,
Humans,
Hypersensitivity,
Implementation Science,
Information Technology,
Patient Participation,
Research,
Translational Research, Biomedical